Acute cholestatic hepatitis probably associated with risperidone

International Journal of Psychiatry in Medicine

Volumn 35, Issue 2, 2005, Pages 199-205

  Tello, Francisca Llinares ^a,b   Prats, Carmen Hernández ^a   Ros, Nuria Bosacoma ^a   Martínez, Enrique Pérez ^a   Grana, Eduardo Climent ^a   Navarro Polo, José Noé ^a   Ordovás Baines, Juan Pablo ^a  

^a Alicante General Hospital   (Spain)

^b NONE   (Spain)

Author keywords

Cholestatic hepatitis; Fluoxetine; Risperidone

Indexed keywords

FLUOXETINE; HALOPERIDOL; LIVER ENZYME; RISPERIDONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE DISEASE; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHOLESTATIC HEPATITIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; DRUG SUBSTITUTION; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; MALE;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; HEPATITIS, TOXIC; HUMANS; MALE; MIDDLE AGED; RISPERIDONE;

EID: 27844482927     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.2190/5XRB-D2XX-X8AH-32KB     Document Type: Article

References (20)

1. Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale 2002;28: 542-551.
2. Kaplowitz N, Aw TY, Simon FR, Stolz A. Drug-induced hepatotoxicity. Annals of Internal Medicine 1986;104:826-839.
3. Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW. Hepatotoxicity of clozapine. Journal of Clinical Psychopharmacology 1997;17:314-317.
4. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996;124:159-167.
5. Casey DE. The relationship of pharmacology to side effects. Journal of Clinical Psychiatry 1997;58:55-62.
6. Chouinard G, Arnott W. Clinical review of risperidone. Canadian Journal of Psychiatry 1993;38:89-95.
7. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 1994;151:825-835.
8. Grunhage F, Fischer HP, Sauerbruch T, Reichel C. Drug- and toxin-induced hepatotoxicity. Z Gastroenterology 2003;41:565-578.
9. Velayudham LS, Farrell GC. Drug-induced cholestasis. Expert Opinion on Drug Safey 2003;2:287-304.
10. Dienstag JL, Isselbacher KJ. Acute hepatitis. In: Isselbacher KJ, Braunwald E, Wilson JD, editors. Harrison's principles of internal medicine. New York: McGraw-Hill, 1994:1458-1477.
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapy 1981;30:239-245.
12. Fuller MA, Simon MR, Freedman L. Risperidone-associated hepatotoxicity. Journal of Clinical Psychopharmacology 1996;16:84-85.
13. Kumra S, Herion D, Jacobsen LK, Briguglia C, Grothe D. Case study: Risperidone-induced hepatotoxicity in pediatric patients. Journal of the American Academy of Child Adolescent Psychiatry 1997;36:701-705.
14. Benazzi F. Risperidone-induced hepatotoxicity. Pharmacopsychiatry 1998;31:241.
15. Phillips EJ. Rapid onset of risperidone-induced hepatotoxicity. Annals of Pharmacotherapy 1998;32:843.
16. Krebs S, Dormann H, Muth-Selbach U, Hahn EG, Brune K, Schneider T. Risperidone-induced cholestatic hepatitis. European Journal of Gastroenterology and Hepatology 2001;13:67-69.
17. Cordeiro Q, Elkins H. Pancreatitis and cholestatic hepatitis induced by risperidone. Journal of Clinical Psychopharmacology 2001;21:529-530.
18. Sharif ZA. Pharmacokinetics, metabolism and drug-drug interactions of atypical antipsychotics in special populations. Primary Care Companion Journal to Clinical Psychiatry 2003;5:22-25.
19. Bondolfi G, Eap CB, Bertschy G, Zullino D, Vermeulen A, Baumann P. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 2001,35:50-56.
20. Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Gatti G, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction. Journal of Clinical Psychopharmacology 2002;22:419-422.